4.5 Article

INTRA-VISCERAL INSULAR CORTEX 2-ARACHIDONOYLGLYCEROL, BUT NOT N-ARACHIDONOYLETHANOLAMIDE, SUPPRESSES ACUTE NAUSEA-INDUCED CONDITIONED GAPING IN RATS

Journal

NEUROSCIENCE
Volume 286, Issue -, Pages 338-344

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuroscience.2014.11.058

Keywords

visceral insular cortex; 2-arachidonoylglycerol; anandamide; endocannabinoid; rat; gape

Categories

Funding

  1. Natural Sciences and Engineering Research Council of Canada [NSERC: 92057]
  2. Canadian Institutes of Health Research [CIHR: 334086]
  3. NSERC Canada Graduate Scholarship

Ask authors/readers for more resources

The visceral insular cortex (VIC) has previously been shown to play a critical role during acute nausea-induced conditioned gaping in rats. Specifically, localized administration of the conventional anti-emetic, ondansetron or the synthetic cannabinoid, HU210, interferes with the establishment of conditioned gaping, likely by reducing the effects of an illness-inducing treatment. However the precise role of the VIC in endocannabinoid-suppression of nausea remains unknown; thus we investigated the potential of localized intra-VIC endocannabinoid administration to interfere with acute nausea-induced conditioned gaping behavior in male Sprague-Dawley rats. Animals received an intraoral infusion of saccharin (0.1%) followed by intra-VIC exogenous N-arachidonoylethanolamide (AEA; 0.4, 4 mu g) or 2-arachidonoylglycerol (2-AG; 0.5, 1 mu g), and were subsequently injected with nausea-inducing LiCl (0.15 M) 15 min later. Bilateral intra-VIC infusions of 2-AG (1 mu g, but not 0.5 mu g) dose-dependently suppressed conditioned gaping, whereas exogenous AEA was without effect. Interestingly, 2-AG reduced conditioned gaping despite additional pretreatment with the selective cannabinoid receptor type 1 (CB1) antagonist, AM-251; however, concomitant pretreatment with the cyclooxygenase inhibitor, indomethacin (0.5 mu g), blocked the suppressive effects of intra-VIC 2-AG. These findings suggest that the modulatory role of the endocannabinoid system during nausea is driven largely by the endocannabinoid, 2-AG, and that its anti-nausea effects may be partly independent of CB1-receptor signaling through metabolic products of the endocannabinoid system. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available